BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21909195)

  • 1. Subclinical infiltration of Basal cell carcinoma in asian patients: assessment after mohs micrographic surgery.
    Ro KW; Seo SH; Son SW; Kim IH
    Ann Dermatol; 2011 Aug; 23(3):276-81. PubMed ID: 21909195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of basal cell carcinoma subtype with histologically confirmed subclinical extension during Mohs micrographic surgery: A prospective multicenter study.
    Lim GF; Perez OA; Zitelli JA; Brodland DG
    J Am Acad Dermatol; 2022 Jun; 86(6):1309-1317. PubMed ID: 35231546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical margins required for basal cell carcinomas treated with Mohs micrographic surgery according to tumor features.
    Cerci FB; Kubo EM; Werner B; Tolkachjov SN
    J Am Acad Dermatol; 2020 Aug; 83(2):493-500. PubMed ID: 32289390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micronodular basal cell carcinoma. A deceptive histologic subtype with frequent clinically undetected tumor extension.
    Hendrix JD; Parlette HL
    Arch Dermatol; 1996 Mar; 132(3):295-8. PubMed ID: 8607634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low recurrence rate of head and neck basal cell carcinoma treated with Mohs micrographic surgery: A retrospective study of 1021 cases.
    Kuiper EM; van den Berge BA; Spoo JR; Kuiper J; Terra JB
    Clin Otolaryngol; 2018 Oct; 43(5):1321-1327. PubMed ID: 29953746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basal cell carcinomas of the ear are more aggressive than on other head and neck locations.
    Mulvaney PM; Higgins HW; Dufresne RG; Cruz AP; Lee KC
    J Am Acad Dermatol; 2014 May; 70(5):924-6. PubMed ID: 24629996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Melanoma Skin Cancer Tumor's Characteristics and Histologic Subtype as a Predictor for Subclinical Spread and Number of Mohs Stages required to Achieve Tumor-Free Margins.
    Santos-Arroyo A; Carrasquillo OY; Cardona R; Sánchez JL; Valentín-Nogueras S
    P R Health Sci J; 2019 Mar; 38(1):40-45. PubMed ID: 30924914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adamantinoid basal cell carcinoma: a predictor of more-aggressive clinical behavior.
    Berk DR; Ball Arefiev KL; Gladstone HB
    Dermatol Surg; 2012 Aug; 38(8):1346-50. PubMed ID: 22551358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Australian Mohs database, part I: periocular basal cell carcinoma experience over 7 years.
    Malhotra R; Huilgol SC; Huynh NT; Selva D
    Ophthalmology; 2004 Apr; 111(4):624-30. PubMed ID: 15051192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can basal cell carcinoma lateral border be determined by fluorescence diagnosis?: Verification by Mohs micrographic surgery.
    El Hoshy K; Bosseila M; El Sharkawy D; Sobhi R
    Photodiagnosis Photodyn Ther; 2016 Jun; 14():4-8. PubMed ID: 26790611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appropriate use criteria for basal cell carcinoma Mohs surgery at a single center in the face of high-burden skin cancer: a retrospective cohort study.
    Fantini BC; Bueno Filho R; Chahud F; Souza CDS
    J Dermatolog Treat; 2019 Feb; 30(1):74-80. PubMed ID: 29727201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dermoscopic and Histopathologic Analysis of the Correlation between the Pigmentation of Basal Cell Carcinoma and Tumor Aggressiveness.
    Park JH; Jo JY; Park H; Kim IH
    Ann Dermatol; 2023 Dec; 35(6):451-460. PubMed ID: 38086359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of histologic subtypes of primary basal cell carcinoma and number of Mohs stages required to achieve a tumor-free plane.
    Orengo IF; Salasche SJ; Fewkes J; Khan J; Thornby J; Rubin F
    J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):395-7. PubMed ID: 9308552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mohs micrographic surgery for basal cell carcinoma: evaluation of the indication criteria and predictive factors for extensive subclinical spread.
    Hoorens I; Batteauw A; Van Maele G; Lapiere K; Boone B; Ongenae K
    Br J Dermatol; 2016 Apr; 174(4):847-52. PubMed ID: 26595159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Misclassification of Aggressive Basal Cell Carcinoma Subtypes and Implications for Management.
    Moon D; Randall G; Higgins S; Sutton AV; Wysong A
    Dermatol Surg; 2021 May; 47(5):593-598. PubMed ID: 33905389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difference between pigmented and nonpigmented basal cell carcinoma treated with Mohs micrographic surgery.
    Aoyagi S; Nouri K
    Dermatol Surg; 2006 Nov; 32(11):1375-9. PubMed ID: 17083591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of curettage in delineating margins of basal cell carcinoma before Mohs micrographic surgery.
    Ratner D; Bagiella E
    Dermatol Surg; 2003 Sep; 29(9):899-903. PubMed ID: 12930329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological factors influencing the number of stages of Mohs surgery for basal cell carcinoma.
    Calvão J; Pinho A; Brinca A; Vieira R
    An Bras Dermatol; 2022; 97(3):291-297. PubMed ID: 35379511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost Analysis of Mohs Micrographic Surgery in High-Risk Facial Basal Cell Carcinoma.
    Blázquez-Sánchez N; de Troya-Martín M; Frieyro-Elicegui M; Fúnez-Liébana R; Martín-Márquez L; Rivas-Ruiz F
    Actas Dermosifiliogr; 2010 Sep; 101(7):622-628. PubMed ID: 28709544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basal cell carcinoma treated with Mohs surgery in Australia I. Experience over 10 years.
    Leibovitch I; Huilgol SC; Selva D; Richards S; Paver R
    J Am Acad Dermatol; 2005 Sep; 53(3):445-51. PubMed ID: 16112351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.